Investigational drug · Phase 3
SPG302
Also called: Tazbentetol
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Alzheimer Disease, Schizophrenia, Amyotrophic Lateral Sclerosis.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
7
Any phase or sponsor naming "SPG302"
First trial start
2024
Jul 29, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SPG302", any sponsor or status.
Conditions studied
As listed on its trial records.
- Alzheimer Disease
- Schizophrenia
- Amyotrophic Lateral Sclerosis
Approved drugs for the same conditions: Alzheimer's disease · ALS (amyotrophic lateral sclerosis) · Schizophrenia · Neurology · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "SPG302" as an intervention, largest first.
- Efficacy and Safety of Tazbentetol in ALS ParticipantsPivotal-lookingNot yet recruiting
SpinogenixIndustry
NCT07325591 · 430 participants (planned) · Start Oct 1, 2026 · Primary completion Dec 31, 2027
Drug: Tazbentetol; placebo · For: Amyotrophic Lateral Sclerosis
SpinogenixIndustry
NCT05882695 · 88 participants · Start Jul 3, 2023 · Primary completion Jun 27, 2025
Drug: SPG302; Placebo · For: Amyotrophic Lateral Sclerosis
Sites: North Ryde, Australia; Herston, Australia; Adelaide, Australia · 4 sites in all
- Study of SPG302 in Adults With SchizophreniaActive, not recruiting
SpinogenixIndustry
NCT06442462 · 32 participants (planned) · Start Aug 1, 2024 · Primary completion Mar 2026
Drug: SPG302; Placebo · For: Schizophrenia
Sites: Garden Grove, California; Box Hill, Australia; Melbourne, Australia
- Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD)Active, not recruiting
SpinogenixIndustry
NCT06427668 · 24 participants · Start Jul 29, 2024 · Primary completion Dec 2025
Drug: SPG302; Placebo · For: Alzheimer Disease
Sites: Sydney, Australia; Adelaide, Australia
SpinogenixIndustry
NCT06903286 · 16 participants · Start May 29, 2025 · Primary completion Jun 30, 2025
Drug: SPG302 · For: Amyotrophic Lateral Sclerosis (ALS)
Sites: North Ryde, Australia; Herston, Australia; Adelaide, Australia
SpinogenixIndustry
NCT06833281 · 12 participants · Start Mar 25, 2025 · Primary completion Jul 30, 2025
Drug: SPG302 · For: Alzheimer's Disease
Sites: Sydney, Australia; Adelaide, Australia
SpinogenixIndustry
NCT07088159
Drug: Tazbentetol · For: ALS (Amyotrophic Lateral Sclerosis)
Sites: Birmingham, Alabama; Scottsdale, Arizona; Los Angeles, California · 16 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- SPG302 mitigates diabetic retinal neuropathy and inner retinal damage in a genetic mouse model of diabetes.
Vanderklish PW, Bastola T, Secrest P, et al. · Exp Eye Res 2026
- Glutamate Metabotropic Receptors-Linked Postsynaptic Density Proteins: An Emergent Hub for Antipsychotics' Regulation of Synaptic Plasticity and Metaplasticity.
Barone A, Vellucci L, Nasti A, et al. · Biomolecules 2026
- SPG302 protects retinal ganglion cells and preserves visual function by preserving synaptic activity in a mouse model of glaucoma.
Bastola T, Choi S, Shen Z, et al. · Exp Eye Res 2025
- Novel regenerative drug, SPG302 promotes functional recovery of diaphragm muscle activity after cervical spinal cord injury.
Fogarty MJ, Zhan WZ, Simmon VF, et al. · J Physiol 2023
- SPG302 Reverses Synaptic and Cognitive Deficits Without Altering Amyloid or Tau Pathology in a Transgenic Model of Alzheimer's Disease.
Trujillo-Estrada L, Vanderklish PW, Nguyen MMT, et al. · Neurotherapeutics 2021
Also in development for Alzheimer Disease
- KarX-ECBMS-986519, Xanomeline Enteric-coatedPhase 39 trials
Bristol Myers Squibb · Alzheimer Disease, Alzheimer's Disease, Irritability Associated With Autism Spectrum Disorder
- ITI-1284JNJ-99245354Phase 36 trials
Intra-Cellular Therapies, Inc. · Generalized Anxiety Disorder, Agitation Associated With Alzheimer's Dementia, Psychotic Disorders
- AXS-05dextromethorphan-bupropionPhase 33 trials
Axsome Therapeutics, Inc. · Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Smoking Cessation
- MasitinibAB1010Phase 33 trials
AB Science · Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Alzheimer Disease
- Combined metabolic activatorsPhase 32 trials
ScandiBio Therapeutics AB · Alzheimer Disease, Gout Disease
- DMB-IINN: Latrepirdine, DimebonPhase 32 trials
Bigespas LTD · Alzheimer Type Dementia, Alzheimer Disease, Dementia of Alzheimer Type
- AR1001Phase 31 trial
AriBio Co., Ltd. · Alzheimer Disease
- XTR006[18F]MK 6240, FlorquinitauPhase 31 trial
Sinotau Pharmaceutical Group · Alzheimer Disease, Neurofibrillary Tangle
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.